Paclitaxel

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

Retrieved on: 
Monday, January 8, 2024
Conference, Drug discovery, Lymphoma, Lymphoid leukemia, IND, DLBCL, Antibody, Leukemia, IKZF3, Inflammation, Mantle cell lymphoma, SAN, Society, IKZF1, Therapy, Cancer, Clinical trial, Paclitaxel, Rheumatoid arthritis, Chronic lymphocytic leukemia, B-cell lymphoma, ASH, CLL, NHL, Business development, BTK, Patient, MCL, Pharmaceutical industry

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today outlined key objectives and anticipated milestones for 2024 and provided an overview of recent progress in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • A webcast of Nurix’s ASH presentation is available in the Investors section of the Nurix website under Events and Presentations .
  • Nurix is evaluating daily oral dosing of NX-5948 in a Phase 1a/1b clinical trial in patients with relapsed or refractory B-cell malignancies.
  • Nurix plans to present and publish preclinical work on its wholly owned programs throughout 2024 at appropriate scientific and medical meetings.
  • Research milestones: Nurix expects to achieve multiple research collaboration milestones throughout 2024 from its existing collaborations with Gilead, Sanofi, and Pfizer.

Compass Therapeutics Provides Corporate Update

Retrieved on: 
Friday, January 5, 2024
Patient, CRC, Stage 2, IND, FDA, BTC, Research and development, PD-1, DLL4, CD137, PET, Melanoma, MD, Doctor of Philosophy, Therapy, Mesothelioma, Paclitaxel, Carcinoma, SCLC, Safety, Development, NSCLC, PD-L1, Pharmaceutical industry

As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.

Key Points: 
  • As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.
  • Effective January 9, 2024, Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors.
  • BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.
  • Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and current Chief Executive Officer will transition to President of Research and Development and assume the role of Vice Chair of the Compass board of directors.

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

Retrieved on: 
Friday, January 5, 2024
API, Breast cancer, Paclitaxel, Public, Patient, Anthracycline

This is the fifth major breast cancer medication introduced by Kexing Biopharm, which further enriches its product portfolio for breast cancer treatment.

Key Points: 
  • This is the fifth major breast cancer medication introduced by Kexing Biopharm, which further enriches its product portfolio for breast cancer treatment.
  • Eribulin Mesylate Injection is the fifth breast cancer medication of Kexing Biopharm.
  • This product can form an effective combination with the existing four ones that have been introduced by Kexing Biopharm and are in the process of obtaining overseas registrations.
  • This collaboration provides Kexing Biopharm with exclusive commercialization licensing for Eribulin Mesylate Injection from Xiling Lab Co., Ltd. in 36 countries, including Brazil, Argentina, Singapore, Thailand, Egypt, South Africa, India, and Saudi Arabia and so on.

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024
Oncolytics Biotech, AB, PR, FDA, Breast, Roche, Progression-free survival, Health, AIO, Congress, Society, Pancreatic cancer, Cancer, Oncology, Partnering, Paclitaxel, Anal cancer, Conference, ASCO, ONC, Data, Annual general meeting, Patient, RNA, MBC, TIL, ESMO, Tumor microenvironment, Anal canal, Pancreatic Cancer Action Network, Physician, International, FOLFIRINOX, Survival, Christmas and holiday season, Neoplasm, Toxicity, Poster, Fast Track, Gemcitabine, SCCA, SAN, PDAC, Science Translational Medicine, TSX, Pancreas, Pharmaceutical industry

Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.

Key Points: 
  • Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.
  • "We believe our cash balance and strong data, supported by our active business development program, position us well for 2024."
  • Together, these data provide a strong foundation to support advancing pelareorep into registrational-track studies, starting in 2024," continued Dr Coffey.
  • 2024 Outlook: Dr. Coffey concluded by saying, "Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer.

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024
Oncolytics Biotech, AB, PR, FDA, Breast, Roche, Progression-free survival, Health, AIO, Congress, Society, Pancreatic cancer, Cancer, Oncology, Partnering, Paclitaxel, Anal cancer, Conference, ASCO, ONC, Data, Annual general meeting, Patient, RNA, MBC, TIL, ESMO, Tumor microenvironment, Anal canal, Pancreatic Cancer Action Network, Physician, International, FOLFIRINOX, Survival, Christmas and holiday season, Neoplasm, Toxicity, Poster, Fast Track, Gemcitabine, SCCA, SAN, PDAC, Science Translational Medicine, TSX, Pancreas, Pharmaceutical industry

Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.

Key Points: 
  • Overview: "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy.
  • "We believe our cash balance and strong data, supported by our active business development program, position us well for 2024."
  • Together, these data provide a strong foundation to support advancing pelareorep into registrational-track studies, starting in 2024," continued Dr Coffey.
  • 2024 Outlook: Dr. Coffey concluded by saying, "Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer.

Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients

Retrieved on: 
Tuesday, January 2, 2024
Immunotherapy, Lung cancer, Survival, Risk, ASCO, Shanda, Mortality, Shanghai Chest Hospital, Trial of the century, EFS, Society, Recurrence, Cisplatin, Cancer, MPR, HR, Death, Pemetrexed, World Health Organization, National Medical Products Administration, Patient, Diagnosis, Safety, Paclitaxel, NSCLC, PCR, Pharmaceutical industry

This is the first approved perioperative therapy for lung cancer in China and the second worldwide.

Key Points: 
  • This is the first approved perioperative therapy for lung cancer in China and the second worldwide.
  • In the same year, the number of lung cancer deaths in China amounted to 715,000, accounting for 23.8% of all cancer deaths in China.
  • Amongst these patients, 20%-25% are surgically resectable at first diagnosis, but even after radical surgical treatment, 30%-55% of these patients suffer from post-surgical recurrence and death.
  • One of the first domestic pharmaceutical companies to initiate clinical trials for perioperative immunotherapy, Junshi Biosciences entered the perioperative immunotherapy arena very early on and now holds the broadest spectrum of indications in China.

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Constipation, INN, Leukopenia, Woman, Carcinoma, Lung cancer, Fatigue, Nausea, DNA, Cancer, Neoplasm, Infection, SCLC, Mouth ulcer, Risk management, Anatomy, Paclitaxel, IIA, CHMP, Diarrhea, Fever, ATC, Capsule, European, Disease, Weakness, Mucositis, Anemia, Medical Subject Headings, Febrile neutropenia, European Commission, Cyclophosphamide, Vincristine, International, Neutropenia, Somatic symptom disorder, Aplastic anemia, Language, Cisplatin, Thrombocytopenia, Medication, Select, Patient, Medicine, Vomiting, Ovary, Survival, Ovarian cancer, Cervical cancer, Hair loss, Radiation, Doxorubicin, Committee, Medical device

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Stomach, INN, Risk, HER2, Breast, Tissue, Heart, Cancer, Neoplasm, Cardiotoxicity, Infection, Anatomy, Paclitaxel, IIA, Breast cancer, ATC, European, Allergy, Metastasis, Blood, Capecitabine, MBC, EBC, Safety, Heart failure, MGC, Patient, Medical Subject Headings, Agency, European Commission, Cyclophosphamide, Immune system, Docetaxel, Carboplatin, International, Language, Cisplatin, Select, Enzyme inhibitor, Medicine, FISH, Radiation, Lymph, Arm, European Medicines Agency, Fluorouracil, Doxorubicin, Medical device

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Platinum, Artery, INN, HER2, Histology, Hypertension, Cancer, Neoplasm, Anatomy, Paclitaxel, IIA, Diarrhea, Breast, Fatigue, Breast cancer, ATC, Embolism, Bleeding, VEGF, Weakness, Abdomen, Capecitabine, Pregnancy, Human, Safety, Gynaecology, NSCLC, Patient, Medical Subject Headings, Peritoneum, EGFR, Carboplatin, International, FIGO, Nutrient, Language, Blood, Cisplatin, Rectum, Oxygen, Anthracycline, Select, Ovary, Lung cancer, Allergy, Recurrence, European Medicines Agency, Growth, Doxorubicin, Taxane

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Retrieved on: 
Monday, December 11, 2023
MSD, Pembrolizumab, Stomach, Lenvatinib, Hepatocellular carcinoma, Research, Carboplatin, Progression-free survival, MSI-H, Disease, Merck & Co., Standard of care, Head, RCC, Cancer, Merck, Patient, OS, PFS, Eisai, Paclitaxel, Esophageal cancer, LEAP, Senior, Pharmaceutical industry

The safety profile of LENVIMA plus KEYTRUDA was consistent with that observed in previously reported studies evaluating the combination.

Key Points: 
  • The safety profile of LENVIMA plus KEYTRUDA was consistent with that observed in previously reported studies evaluating the combination.
  • We are grateful to the patients, their loved ones, and the investigators whose participation is what makes scientific advancement possible."
  • LENVIMA plus KEYTRUDA is approved in the U.S., the EU, Japan and other countries for the treatment of certain types of advanced endometrial carcinoma following prior systemic therapy in any setting and advanced renal cell carcinoma (RCC).
  • Results from the LEAP-001 trial do not affect the current approved indications for the KEYTRUDA plus LENVIMA combination or other ongoing trials from the LEAP clinical program.